Daniel Bexell

This study identifies SUMOylation as a therapeutic target in high-risk neuroblastoma, showing that SUMO pathway inhibitors like TAK-981 reduce tumor growth and are effective in combination with other therapies.

This paper introduces EvoBind-multimer, a deep learning framework for designing molecular glues from protein sequences, demonstrating its ability to recruit E3 ligases to oncoproteins and showing context-dependent functionality.

This study shows ALK R1275Q mutation sustains an immature SCP-like cell state during sympathoadrenal commitment, increasing susceptibility to MYCN-driven neuroblastoma initiation.

This study repurposes statins and phenothiazines to treat chemoresistant neuroblastoma, showing synergistic effects and improved survival in preclinical models.